Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1216 participants.

Also called NCT03539445

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,216 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03539445
Other papers using this trial's data
  • Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial JAMA neurology, 2023-08-01 DOI, PubMed 37358859, PMC10294018 Not in the PMC Open Access subset.
  • Favorable Systemic Immune-Inflammation Status Enhances the Neuroprotective Effects of Butylphthalide in Ischemic Stroke: A Post Hoc Analysis of BAST Trial CNS neuroscience & therapeutics, 2026-06 DOI, PubMed 42329209, PMC13285582 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03539445. Randomized; quadruple masking; primary purpose treatment. Start 2018-07-01 (actual); primary completion 2022-05-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
Acronym
BAST
Condition
Acute Ischemic Stroke
Intervention (Drug)
Butylphthalide
Intervention (Drug)
Butylphthalide Placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct03539445
Content hash
31e306f7d14b8d28400077bad01da767413aeece4097b630916a509be7862d7a